ISRCTN55212198 https://doi.org/10.1186/ISRCTN55212198

# Reimbursement for smoking cessation treatment

| Submission date | Recruitment status | [ ] Prospectively registered |
|---|---|---|
| 12/09/2005 | No longer recruiting | [ ] Protocol |
| **Registration date** | **Overall study status** | [ ] Statistical analysis plan |
| 12/09/2005 | Completed | [X] Results |
| **Last Edited** | **Condition category** | [ ] Individual participant data |
| 10/09/2009 | Mental and Behavioural Disorders | |

**Plain English summary of protocol**
Not provided at time of registration

## Contact information

**Type(s)**
Scientific

**Contact name**
Dr J. Kaper

**Contact details**
Care and Public Health Research Institute (CAPHRI), Maastricht University
P.O. Box 616
Maastricht
Netherlands
6200 MD
+31 (0)43 3882420
janneke.kaper@hag.unimaas.nl

## Additional identifiers

**Protocol serial number**
NTR104; STIVORO and the Dutch Asthma Foundation 3.4.03.28

## Study information

**Scientific Title**
(Added 18/08/09) The (cost)-effectiveness of reimbursement for smoking cessation treatment

**Study objectives**

Reimbursement for smoking cessation treatment will increase the use of the treatment and the number of quit attempts. The increased use of smoking cessation treatment by reimbursement will result into increased prolonged abstinence.

## Ethics approval required
Old ethics approval format

## Ethics approval(s)
Approved by the Medical Ethics Committee of the Trimbos Institute in Utrecht, The Netherlands (May 2005).

## Primary study design
Interventional

## Study design
Random consent design

## Study type(s)
Other

## Health condition(s) or problem(s) studied
Smoking cessation

## Interventions
For a period of 6 months, smokers in the intervention group had the opportunity to apply for reimbursement for SCT. They received a leaflet with a description of the SCTs for which reimbursement was available, and information on how to receive the reimbursement. Smokers in the intervention group could receive full reimbursement for pharmacological treatment (bupropion and NRT (chewing gum, patch, tablet, sublingual tablet and inhaler)), behavioural counselling (written advice, telephone or face to face counselling) or a combination. To receive reimbursement, they had to send the receipt and two statements of personal contact with a health care professional (general practitioner, general practice nurse, physician, psychologist or health community worker) to the health insurance company. Before the study started, all the health care professionals in the study region were informed about the study. No limit was set on the number of applications for reimbursement. In the control, no reimbursement or information about smoking cessation treatment was offered.

## Intervention Type
Other

## Phase
Not Specified

## Primary outcome(s)
The primary outcome measure of the reimbursement study was continuous abstinence from smoking. Continuous abstinence was defined as not having smoked for at least seven days preceding the 6-month and 12-month questionnaire and not having relapsed between both questionnaires. After the 6-month and 12-month questionnaire, quitters were contacted to make an appointment for biochemical validation of their smoking status.

## Key secondary outcome(s)

Secondary outcomes were the use of smoking cessation treatment, the number of quit attempts that were undertaken, and the cost-effectiveness of reimbursement was assessed.

### Completion date
01/05/2003

## Eligibility

### Key inclusion criteria
We included smokers of at least 18 years old and healthcare insured by health insurance company "De Friesland Zorgverzekeraar". Participants did not have to be motivated to quit smoking.

### Participant type(s)
Patient

### Healthy volunteers allowed
No

### Age group
Adult

### Lower age limit
18 Years

### Sex
All

### Key exclusion criteria
Only one smoker per household was allowed to participate.

### Date of first enrolment
01/05/2002

### Date of final enrolment
01/05/2003

## Locations

### Countries of recruitment
Netherlands

### Study participating centre
**Care and Public Health Research Institute (CAPHRI), Maastricht University**
Maastricht
Netherlands
6200 MD

# Sponsor information

### Organisation
CAPHRI research institute, University Maastricht (Netherlands)

### ROR
https://ror.org/02jz4aj89

# Funder(s)

### Funder type
Charity

### Funder Name
Dutch Asthma Foundation (Netherlands)

### Funder Name
STIVORO (Netherlands)

# Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary
Not provided at time of registration

### Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/07/2005 | | Yes | No |
| Results article | results on cost effectiveness | 01/07/2006 | | Yes | No |
| Results article | results on sustained abstinence | 01/11/2006 | | Yes | No |